AAML1921; Bosutinib for Chronic Myeloid Leukemia

AAML1921; Bosutinib for Chronic Myeloid Leukemia

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is no longer recruiting.

Description

This study involves taking a study drug calledbosutinib. The overall goals of this study are to find the bestdose of bosutinib that we can give safely, and to find out what effects, goodand/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML). 

Eligibility and criteria
IRB Number:
20-017915
Eligible age range:
1 years - 17 years
Clinical trial phase:
Phase I
Phase II
Official title:
AAML1921, A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921

What to expect

Participation will last for up to 10 years. Subjectswill receive Bosutinib once daily. Study visits include the followingassessments: blood draws, bone marrow aspirate (if procedure is performed aspart of regular clinical care), collection of extra blood and tissue for futureresearch, and the completion of diaries and questionnaires.
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.